Analyst Price Target is $144.50
▲ +37.23% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Novo Nordisk A/S in the last 3 months. The average price target is $144.50, with a high forecast of $160.00 and a low forecast of $115.00. The average price target represents a 37.23% upside from the last price of $105.30.
Current Consensus is
Moderate Buy
The current consensus among 7 polled investment analysts is to moderate buy stock in Novo Nordisk A/S. This rating has held steady since July 2023, when it changed from a Buy consensus rating.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Read More
